Patents and Heart Valve Surgery - III: Percutaneous Heart Valves.

Faisal H Cheema, Mona Ascha, Mohammad Bin Pervez, Ayesha Mannan, Alex P Kossar, Gianluca Polvani
{"title":"Patents and Heart Valve Surgery - III: Percutaneous Heart Valves.","authors":"Faisal H Cheema, Mona Ascha, Mohammad Bin Pervez, Ayesha Mannan, Alex P Kossar, Gianluca Polvani","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Advancements in technology for the treatment of valvularcardiac diseases seek to provide solutions for high risk patients in the form of percutaneous valve insertion for patients with complicated valvular disease not amenable to more traditional options. Within the last decade, cardiac valves designed for percutaneous insertion have emerged rapidly as a treatment option for valvular disease. This procedure serves as an alternative to open heart surgery, which is more invasive and requires longer ICU stay. Thus, the percutaneous valve insertion procedure has been used on older, frailer patients who are poor candidates for open heart surgery. Designs for percutaneous valve insertion systems have been in development for decades, but have only recently been approved by the FDA for use. Important considerations include stent design, valve design, balloon catheter design, and deployment method.</p>","PeriodicalId":20905,"journal":{"name":"Recent patents on cardiovascular drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on cardiovascular drug discovery","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Advancements in technology for the treatment of valvularcardiac diseases seek to provide solutions for high risk patients in the form of percutaneous valve insertion for patients with complicated valvular disease not amenable to more traditional options. Within the last decade, cardiac valves designed for percutaneous insertion have emerged rapidly as a treatment option for valvular disease. This procedure serves as an alternative to open heart surgery, which is more invasive and requires longer ICU stay. Thus, the percutaneous valve insertion procedure has been used on older, frailer patients who are poor candidates for open heart surgery. Designs for percutaneous valve insertion systems have been in development for decades, but have only recently been approved by the FDA for use. Important considerations include stent design, valve design, balloon catheter design, and deployment method.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
专利与心脏瓣膜手术 - III:经皮心脏瓣膜。
治疗心脏瓣膜疾病的技术不断进步,旨在为高风险患者提供解决方案,为患有复杂瓣膜疾病且无法采用更多传统方法的患者提供经皮瓣膜植入术。近十年来,经皮置入心脏瓣膜作为一种治疗瓣膜病的方法迅速崛起。这种手术可替代创伤更大、需要在重症监护室停留更长时间的开胸手术。因此,经皮瓣膜置入术被用于年龄较大、体质较弱、不适合进行开胸手术的患者。经皮瓣膜置入系统的设计已经发展了几十年,但直到最近才获得美国食品及药物管理局的批准使用。重要的考虑因素包括支架设计、瓣膜设计、球囊导管设计和部署方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Patents and Heart Valve Surgery - III: Percutaneous Heart Valves. Patents and Heart Valve Surgery - III: Percutaneous Heart Valves. New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel. Blockade of renin angiotensin system in heart failure post-myocardial infarction: what is the best therapy? Ticagrelor: a novel drug for an old problem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1